Benzinga · Feb 3, 2026
AD
NASDAQ · ADXN
Addex Therapeutics Ltd
Healthcare · Biotechnology
$3.22
Up+$0.04 (+1.21%)
Updated Oct 10, 2026, 6:42 PM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 4.81M
- P/E ratio
- -0.89
- Dividend yield
- 0.00%
- 52-week range
- $2.56 – $7.60
- Volume
- 4.51K
- Avg. volume
- 6.27K
Price performance · ADXN
ADXN price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
ADXN closed at $3.22 after 21 trading sessions, down 7.78% for the selected period.
- Last close
- $3.22
- Period change
- -7.78%
- Period low
- $2.76
- Period high
- $3.65
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $3.09 | $3.249 | $3.09 | $3.2186 | 4.51K |
| Oct 8, 2026 | $3.22 | $3.23 | $3.00 | $3.18 | 11.68K |
| Oct 7, 2026 | $3.1454 | $3.16 | $2.9773 | $3.13 | 9.4K |
| Oct 6, 2026 | $3.1492 | $3.205 | $3.14 | $3.18 | 1.75K |
| Oct 5, 2026 | $3.11 | $3.13 | $3.10 | $3.10 | 5.9K |
| Oct 2, 2026 | $3.01 | $3.08 | $2.99 | $3.07 | 13.41K |
| Oct 1, 2026 | $2.83 | $2.98 | $2.7842 | $2.98 | 6.91K |
| Sep 30, 2026 | $2.91 | $2.91 | $2.67 | $2.76 | 5.25K |
| Sep 29, 2026 | $2.74 | $2.97 | $2.69 | $2.95 | 31.35K |
| Sep 28, 2026 | $3.69 | $3.74 | $2.56 | $2.81 | 90.66K |
| Sep 25, 2026 | $3.62 | $3.80 | $3.52 | $3.65 | 15.48K |
| Sep 24, 2026 | $3.45 | $3.60 | $3.40 | $3.46 | 7.87K |
| Sep 23, 2026 | $3.48 | $3.54 | $3.4209 | $3.45 | 12.95K |
| Sep 22, 2026 | $3.50 | $3.53 | $3.23 | $3.50 | 4.89K |
| Sep 21, 2026 | $3.35 | $3.53 | $3.3405 | $3.53 | 9.57K |
| Sep 18, 2026 | $3.3698 | $3.44 | $3.3698 | $3.40 | 3K |
| Sep 17, 2026 | $3.35 | $3.45 | $3.29 | $3.36 | 27.24K |
| Sep 16, 2026 | $3.29 | $3.44 | $3.22 | $3.36 | 40.31K |
| Sep 15, 2026 | $3.34 | $3.42 | $3.10 | $3.26 | 24.2K |
| Sep 14, 2026 | $3.3903 | $3.48 | $3.21 | $3.48 | 14.09K |
| Sep 11, 2026 | $3.49 | $3.6516 | $3.30 | $3.49 | 35.6K |
Latest ADXN news
The latest Smart Investors Daily articles mentioning ADXN.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ADXN research
Overview
Company profile and research snapshot.
Company profile
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $30.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 6, 2024 | BAADER HELVEA EQUITY RESEARCH | Sell | — |
| Jun 5, 2024 | BAADER HELVEA EQUITY RESEARCH | Sell | — |
| Nov 29, 2023 | BAADER HELVEA EQUITY RESEARCH | Sell | — |
| Nov 28, 2023 | BAADER HELVEA EQUITY RESEARCH | Sell | — |
| Aug 10, 2023 | BAADER HELVEA EQUITY RESEARCH | Sell | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Dec 4, 2025
Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Transcript
Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call December 4, 2025 10:00 AM ESTCompany ParticipantsTimothy Dyer - Co-Founder, CEO & DirectorMikhail...
seekingalpha.com · Dec 4, 2025
Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Transcript
Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Transcript
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
